[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Picón MJ, Lara JI, Sarasa JL, Recasens JD, Clouet R, Gonzalo MA, Rovira A: Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. Eur J Endocrinol; 2000 Jun;142(6):619
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
  • OBJECTIVE: The aim of this study was to prove the utility of GnRH analogues for the suppression of androgen secretion in a postmenopausal woman with a suspected virilizing ovarian tumour.
  • DESIGN AND METHODS: We present a case of a 72-year-old woman with virilization of recent onset.
  • Computed axial tomography scan of the ovaries was normal and the adrenal glands showed a discrete enlargement.
  • In order to achieve a diagnosis, the patient was submitted to a laparotomy that revealed a small hilus cell tumour in the left ovary.
  • CONCLUSION: GnRH analogues may offer a good therapeutic option in some states of gonadotrophin-dependent hyperandrogenism of ovarian origin.

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10822225.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


2. Ogawa S, Fukunaga K, Hiraoka R, Kohda E, Yamaguchi K, Ito D, Hata J: A case of poorly differentiated hilar lung adenocarcinoma of an unidentified histological type. Keio J Med; 2000 Dec;49(4):162-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of poorly differentiated hilar lung adenocarcinoma of an unidentified histological type.
  • The shadow of a mass was seen at the hilum of the left lung, and the mediastinal lymph nodes on both sides were swollen.
  • No histological diagnosis was obtained even after bronchoscopy, including transbronchial needle aspiration biopsy, but large-cell carcinoma of the lung was diagnosed on the basis of ultrasound-guided biopsy of a shadow in the liver suspected of being a metastatic tumor (T2N3M1, Stage IV).
  • Two courses of chemotherapy (CBCDA + VDS) failed to gain any improvement, and the pain resulting from recurrent bone metastases was managed mainly by the administration of the best supportive care.
  • Autopsy revealed a primary hilar lung tumor with a histological diagnosis of poorly differentiated adenocarcinoma.
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Cell Differentiation. Diagnosis, Differential. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11192985.001).
  • [ISSN] 0022-9717
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Lyons G, Quadrelli S, Silva C, Vera K, Iotti A, Venditti J, Chertcoff J, Chimondeguy D: Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor. J Thorac Oncol; 2008 Sep;3(9):989-93
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor.
  • INTRODUCTION: The tumor, node, metastasis (TNM) system has been recognized internationally as the standard for staging disease extension, but despite the improvements of the 1997/2002 international staging system, there may be marked differences in postoperative 5-year survival rates within each stage.
  • There is controversy about the impact of tumor size itself as a variable unrelated to stage.The objective of this study was to analyze the influence of tumor size on the survival in patients with surgically resected non-small cell lung carcinoma (NSCLC).
  • METHODS: Between August 1985 and January 2006, 400 patients underwent pulmonary resection with a curative intention for non-small cell lung carcinoma.
  • Patients were excluded if they had received neoadjuvant chemotherapy.
  • The clinicopathological records of each patient were examined for prognostic factors such as age, sex, right or left side cancer, histology, tumor location, tumor size, clinical nodal stage number, and distribution of metastatic nodes.
  • Adenocarcinoma was the most common type (n = 245, 61.2%).
  • When only patients without neoplastic hilar or mediastinal metastases (pN0) were included, the difference in survival was significantly different in terms of tumor size (log rank 28.46, p < 0.0001).
  • In the multivariate analysis, tumor size and the T factor were found to have maintained its independent prognostic effects on overall survival.
  • Among patients with pN0 tumors smaller that 15 mm in diameter, 5-year survival was 95% whereas patients with tumors bigger than 16 mm in diameter had a 5-year survival of 65% (p < 0.0001).
  • CONCLUSION: In conclusion, our data suggest that tumors over 15 mm are associated with shorter 5-year survival in all TNM stages.
  • Current TNM categories are not sufficiently discriminatory and the T factor requires to be reevaluated in further revisions of the TNM classification.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / mortality. Lung Neoplasms / pathology
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / mortality. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Raz DJ, Odisho AY, Franc BL, Jablons DM: Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg; 2006 Nov;132(5):1189-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
  • OBJECTIVE: Bronchioloalveolar carcinoma is a clinically heterogeneous subtype of non-small cell lung carcinoma that frequently has low 2-[18F]fluoro-D-glucose (FDG) uptake on positron emission tomographic scanning.
  • We investigated whether tumor FDG avidity was associated with worse survival among patients with completely resected node-negative pure and mixed bronchioloalveolar carcinoma.
  • METHODS: We performed a cohort study of 36 patients who had completely resected pure and mixed bronchioloalveolar carcinoma between 1998 and 2004, who had no hilar or mediastinal lymph node metastases, and who had undergone a preoperative positron emission tomographic scan.
  • Tumor FDG avidity was defined as a standardized uptake value of 2.5 or greater.
  • Survival analysis was performed with a proportional hazards model.
  • Seventeen patients (47%) had FDG-avid tumors, and 19 patients (53%) had non-avid tumors.
  • FDG avidity had a hazard ratio of death of 8.6 (95% confidence interval 1.4-244.7, P = .02) after adjusting for tumor size, the presence of multifocal bronchioloalveolar carcinoma, and the presence of histologically mixed bronchioloalveolar carcinoma.
  • CONCLUSIONS: Preoperative tumor FDG standardized uptake value of 2.5 or greater on positron emission tomography is a powerful predictor of long-term mortality in patients with lymph node-negative pure and mixed bronchioloalveolar carcinoma who undergo complete surgical resection.
  • Patients with a high level of FDG uptake (standardized uptake value > or = 2.5) may benefit from adjuvant chemotherapy or more frequent clinical follow-up.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059942.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-02; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCRR NIH HHS / RR / M01 RR-00079; United States / NCI NIH HHS / CA / R01 CA093708-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Tokuyasu H, Izumi H, Mukai N, Takeda K, Sakaguchi Y, Isowa N, Shimizu E: Small cell lung cancer complicated by pulmonary sarcoidosis. Intern Med; 2010;49(18):1997-2001
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell lung cancer complicated by pulmonary sarcoidosis.
  • Chest radiography and computed tomography showed mediastinal and bilateral hilar lymphadenopathy.
  • Histological examination of the biopsy specimens obtained from the tumor in the left upper bronchus revealed small cell lung cancer, whereas examination of the specimens obtained from the left B(3) revealed noncaseating epithelioid cell granulomas containing giant cells, confirming the diagnosis of sarcoidosis.
  • The patient underwent chemotherapy with carboplatin and etoposide without any steroids.
  • After 4 courses of chemotherapy, bronchoscopic examination revealed that the tumor had shrunk, and the BALF CD4/CD8 ratio had decreased; further, no histological evidence of sarcoidosis was seen in specimens obtained from the left B(3).
  • Concomitant small cell lung cancer and sarcoidosis is rare.
  • Interestingly, cancer chemotherapy might improve pulmonary sarcoidosis.
  • [MeSH-major] Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Sarcoidosis, Pulmonary / complications. Sarcoidosis, Pulmonary / diagnosis. Small Cell Lung Carcinoma / complications. Small Cell Lung Carcinoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847506.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Voutsas V, Mylonaki E, Gymnopoulos K, Kapetangiorgis A, Grigoriadis C, Papaemanuell S, Vafiadis E, Christaki P: Paraneoplastic limbic encephalitis as a cause of new onset of seizures in a patient with non-small cell lung carcinoma: a case report. J Med Case Rep; 2008;2:270

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic limbic encephalitis as a cause of new onset of seizures in a patient with non-small cell lung carcinoma: a case report.
  • CASE PRESENTATION: This case report describes the new onset of seizures in a 64-year-old male patient receiving chemotherapy for a diagnosed stage IV non-small cell lung carcinoma.
  • After three cycles of therapy, he was re-evaluated with a chest computed tomography which showed a 50% reduction in the tumor mass and in the size of the hilar and mediastinal lymphadenopathy.
  • Twenty days after the fourth cycle of chemotherapy, the patient was admitted to a neurological clinic because of the onset of self-limiting complex partial seizures, with motionless stare and facial twitching, but with no signs of secondary generalization.
  • The patient had also recently developed neurological symptoms of short-term memory loss and temporary confusion, and behavioral changes.
  • Based on the clinical picture, the patient's history of lung cancer, the brain magnetic resonance imaging findings and the results of the brain biopsy, we concluded that our patient had a 'definite' diagnosis of paraneoplastic limbic encephalitis and he was subsequently treated with a combination of chemotherapy and oral steroids, resulting in stabilization of his neurological status.
  • Despite the neurological stabilization, a chest computed tomography which was performed after the 6th cycle showed relapse of the disease in the chest.
  • CONCLUSION: Paraneoplastic limbic encephalitis is a rather rare cause of new onset of seizures in patients with non-small cell lung carcinoma.
  • Incidence, clinical presentation, laboratory evaluation, differential diagnosis, prognosis and treatment of this entity are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orphanet J Rare Dis. 2007;2:22 [17480225.001]
  • [Cites] Oncologist. 2006 Mar;11(3):292-305 [16549814.001]
  • [Cites] Age Ageing. 2005 Mar;34(2):190-3 [15713869.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1481-94 [10869059.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40 [15258215.001]
  • [Cites] Brain. 2001 Jun;124(Pt 6):1138-48 [11353730.001]
  • [Cites] Brain. 1997 Jun;120 ( Pt 6):923-8 [9217677.001]
  • (PMID = 18700972.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526091
  •  go-up   go-down


7. Ma J, Wen ZS, Lin P, Wang X, Xie FY: The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J Cancer; 2010 Sep;29(9):787-95
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases.
  • Solitary metastatic lung tumor from NPC is a distinctive group associated with a better survival.
  • This study was to find a more effective treatment modality and prognostic factors for the group.
  • METHODS: Clinical data of 105 cases of solitary metastatic lung tumor from NPC were retrospectively analyzed.
  • The Cox univariate and multivariate analyses of gender, age, pathologic type, stage, adjuvant chemotherapy, evaluation of treatment for NPC, disease-free interval, size of metastatic tumor, pulmonary hilar and/or mediastinal lymph node metastasis, treatment modalities, recurrent distant metastases and/or relapse of NPC were conducted.
  • RESULTS: The local control rate was 53.8% in chemotherapy group, 88.0% in radiotherapy ± chemotherapy group, and 96.4% in operation ± chemotherapy group (P < 0.01).
  • The most promising progression-free survival (PFS) and overall survival (OS) were obtained with operation ± chemotherapy and followed by radiotherapy ± chemotherapy.
  • Both of them showed much better efficacy than chemotherapy (P < 0.001).
  • The T stage of NPC, size of metastatic tumor, hilar and/or mediastinal lymph node metastasis, and the treatment modality were independent prognostic factors.
  • CONCLUSIONS: Operation ± chemotherapy and radiotherapy ± chemotherapy are better treatment of solitary metastatic lung tumor from NPC, which could improve the local control and prolong the PFS and OS.
  • Chemotherapy is recommended for patients with higher T stage of NPC, size of metastatic tumor ≥ 3 cm, pulmonary hilar and/or mediastinal lymph node metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy / methods. Radiotherapy, High-Energy. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20800020.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Rosell R, Green M, Gumerlock P: Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage. Semin Oncol; 2001 Feb;28 Suppl 2:28-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage.
  • Increasing evidence that non-small cell lung cancer is a systemic disease from the outset confirms the rationale for adjuvant chemotherapy.
  • The position is clearer in the case of neoadjuvant therapy because long-term follow up of two trials now shows that patients randomized to chemotherapy before surgery were significantly more likely to survive to 5 years than patients treated with surgery alone.
  • Early data suggest that neoadjuvant chemotherapy based on docetaxel (Taxotere; Aventis, Antony, France) (possibly used sequentially with other agents) may be as effective as older regimens and better tolerated.
  • Because p53 status influences the expression of microtubule-associated proteins and hence the sensitivity of a tumor to taxanes, it is possible that molecular markers could be used to customize chemotherapy to individual patients.
  • Generally, it is becoming clearer that molecular staging is a more sensitive means of demonstrating tumor dissemination than light microscopy.
  • The Cancer and Leukemia Group B is undertaking a prospective study using reverse transcriptase-polymerase chain reaction to detect MUC-I RNA in bone marrow and hilar and mediastinal lymph nodes removed at resection with the aim of distinguishing between stage I patients likely to remain disease-free for long periods and those at high risk of relapse.
  • A study of small cell lung cancer is using automated fluorescence microscopy to detect keratin-positive cells in the marrow and blood of patients who have a complete response to initial therapy but are nevertheless at high overall risk of relapse.
  • The identification of genetic lesions in a high proportion of patients with non-small cell lung cancer may guide the development of new therapies aimed at increasing rates of apoptosis among tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140079.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Morita M, Toyoshima H, Iino K, Tomita K, Sasaki H: [A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Mar;35(3):479-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].
  • The patient was a 63-year-old man who consulted our hospital with complaints of a cough and breathing difficulties.
  • His chest CT revealed a 25-mm mass in his right S1 hilar area with spiculation, disseminated nodule in right lung, and pericardial effusions.
  • Also, bronchoscope and TBLB revealed squamous cell carcinoma.
  • This patient was diagnosed as lung cancer (cT4N3M1, stage IV), and chemotherapy was initiated.
  • The chemotherapy was given in the order of CBDCA (AUC3) +GEM (1,000 mg/m(2)), DOC (60 mg/m(2)), and VNR (25 mg/m(2)), and the tumor response was PD.
  • S- 1 (120 mg/body/day, continuous administration for 2 weeks followed by 1 week of rest) was chosen as fourth-line treatment, and a breast CT detected tumor size reduction following completion of the first course.
  • However, after completion of three courses, the breast CT found tumor-enlargement again.
  • Then the chemotherapy was changed to amrubicin (35 mg/m(2)), but the treatment was discontinued due to skin rash.
  • We once experienced a size reduction with S-1, so S-1 (100 mg/body/day, day 1-14) plus CPT-11 (60 mg/m(2), day 1, 7, 14) combination chemotherapy was conducted at 4-week intervals.
  • After two courses were completed, tumor size reduction was observed by breast XP and CT.
  • Currently, seven courses were completed, and we will continue this treatment due to the tumor response of SD.
  • The S-1 single treatment and S-1+CPT-11 combination chemotherapy showed efficacy for this difficult case of NSCLC with refractoriness to multiple cancer drug chemotherapy.
  • This combination treatment should be investigated further for its therapeutic benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Neoplasm / drug effects. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Drug Combinations. Humans. Keratin-19. Keratins / blood. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347399.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0 / Keratin-19; 0 / antigen CYFRA21.1; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 68238-35-7 / Keratins; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Ohyama S, Hatachi Y, Ueda T, Nakata M, Taniguchi M, Hasegawa Y, Murayama T, Bando K: [An elderly patient with advanced non-small-cell lung cancer that responded remarkably to combination chemotherapy of vinorelbine and gemcitabine]. Gan To Kagaku Ryoho; 2002 Mar;29(3):439-42
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly patient with advanced non-small-cell lung cancer that responded remarkably to combination chemotherapy of vinorelbine and gemcitabine].
  • A chest CT revealed a mass shadow in the right upper lobe and enlarged hilar and pretracheal lymph nodes.
  • After 4 courses of chemotherapy, the primary tumor and hilar lymph node were remarkably reduced in size, and his hemoptysis disappeared and body weight increased.
  • It is suggested that combination chemotherapy with vinorelbine and gemcitabine is effective for elderly patients with non-small-cell lung cancer with good performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


11. Kambayashi T, Ri M, Yanagihara K, Miyahara R, Bando T, Hasegawa S, Inui K, Wada H: [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel]. Gan To Kagaku Ryoho; 2003 Jun;30(6):841-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel].
  • A 69-year-old man had undergone low anterior resection and a right lobe resection of the liver for rectum cancer and metastatic liver tumor at the age of 66 years.
  • He presented at our hospital because of an abnormal shadow on a CT chest scan, which indicated a tumor shadow 2.5 cm in size in the lingular lobe and enlarged hilar and mediastinal lymph nodes.
  • A bronchoscopic tumor biopsy revealed pulmonary metastasis from the rectum cancer.
  • Bronchoscopic examination also identified an endobronchial squamous cell lung cancer, which almost completely obstructed the orifice of B1 and B2.
  • We concluded that the patient had squamous cell lung cancer with metastases in the mediastinal lymph nodes.
  • He was initially treated with weekly chemotherapy with carboplatin (AUC 1.25) and paclitaxel (70 mg/m2).
  • The endobronchial tumor was markedly reduced in size after 2 weeks of the chemotherapy.
  • Furthermore, after 6 weeks of the chemotherapy, the tumor had disappeared completely, and 11 days later, lower division segmentectomy and hilar and mediastinal lymph node dissection were performed.
  • The patient has continued to receive chemotherapy as an outpatient and has been well without recurrence of any metastases for over 16 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Humans. Lymphatic Metastasis. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852353.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 8
  •  go-up   go-down


12. Ohno S, Takemasa A, Kawaguchi K, Teruuchi S, Saitoh N, Hasegawa T, Yamaguchi T, Sohara Y, Hironaka M, Sugiyama Y: [Induction chemotherapy (cisplatin + vinorelbine) is found to be markedly effective for squamous cell lung carcinoma with sarcoidosis--a case report]. Gan To Kagaku Ryoho; 2001 Feb;28(2):235-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy (cisplatin + vinorelbine) is found to be markedly effective for squamous cell lung carcinoma with sarcoidosis--a case report].
  • A sixty-one-year-old man was admitted to our hospital because of a right lung tumor shadow.
  • He was newly diagnosed as having squamous cell carcinoma by trans bronchial biopsy.
  • He was treated with an induction chemotherapy (cisplatin 80 mg/m2 + vinorelbine 20 mg/m2) followed by right middle and lower lobectomy with a mediastinal nodal dissection, because the stage of his carcinoma was cT2N2M0.
  • Resected lung tissue showed the disappearance of cancer cells.
  • Dissected mediastinal and hilar lymph nodes showed many sarcoid granulomas.
  • Cisplatin combined with vinorelbine might be an effective chemotherapy for non-small cell lung carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Sarcoidosis / complications. Vinblastine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242653.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


13. Shimizu K, Watanabe E, Hamanaka S, Onuma S, Nakano M, Yamazaki T, Higa M, Yamamuro W, Kiguchi E: [A case of non-small-cell lung cancer successfully treated using combination chemotherapy with CDDP and vinorelbine]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1565-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-small-cell lung cancer successfully treated using combination chemotherapy with CDDP and vinorelbine].
  • A 67-year-old woman presented to our hospital with a chief complaint of bloody sputum.
  • A plain chest X-ray a CT scan revealed a tumor shadow 3 cm in size in the middle lobe of the right lung, multiple nodular shadows in the bilateral lung fields and enlarged hilar and mediastinal lymph nodes.
  • A tumor biopsy done under bronchoscopy revealed poorly differentiated adenocarcinoma of the lungs (cT2N3M1).
  • She was given two courses of combination therapy consisting of cisplatin (80 mg/m2) and vinorelbine (20 mg/m2).
  • The primary tumor in the middle lobe of the right lung and the lung metastases were markedly reduced in size, and a complete response was obtained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016002.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Tamura M, Doba S, Funaki K, Sasaki S, Michiwa Y, Kurosaka Y, Takekawa S, Kiriyama M, Kojima Y, Kita T, Kawashima A: [A case of non-small cell lung cancer in which complete response was achieved with chemotherapy including cisplatin, vinorelbine, mitomycin C, followed by additional cisplatin, etoposide and concurrent radiotherapy]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1611-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-small cell lung cancer in which complete response was achieved with chemotherapy including cisplatin, vinorelbine, mitomycin C, followed by additional cisplatin, etoposide and concurrent radiotherapy].
  • A 43-year-old man presented at our hospital with a complaint of cough and sputum.
  • A plain chest X-ray and CT scan revealed a tumor shadow 8 cm in size in the right hilar and enlarged mediastinal lymph node.
  • The tumor had invaded the superior vena cava.
  • A tumor biopsy done under bronchoscopy revealed poorly-differentiated adenocarcinoma (cT4N2M0).
  • He was given three courses of a combination therapy consisting of cisplatin (80 mg/m(2)), vinorelbine (25 mg/m(2)) and mitomycin C (8 mg/m(2)).
  • Additionally, concurrent chemoradiotherapy (cisplatin 80 mg/m(2)+etoposide 100 mg/m(2), and 45 Gy) was performed.
  • Right pneumonectomy was performed, because the primary tumor and the enlarged lymph node were markedly reduced in size, and a histological examination of the resected specimen revealed no detectable cancer cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Mitomycin / administration & dosage. Neoplasm Staging. Pneumonectomy. Remission Induction. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108727.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


15. Leelawat K, Udomchaiprasertkul W, Narong S, Leelawat S: Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells. J Cancer Res Clin Oncol; 2010 Oct;136(10):1537-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
  • PURPOSE: Hilar cholangiocarcinoma (Klatskin tumor) is one of the most difficult cancers to treat.
  • We demonstrate activation of phosphoinositide-3-kinase (PI3K)/Akt signaling, which is a critical pathway for cell survival, in hilar cholangiocarcinoma cells.
  • However, inhibition of PI3K has little effect on hilar cholangiocarcinoma cell survival.
  • In this study, we investigated the mechanism by which hilar cholangiocarcinoma cells resist PI3K inhibitors.
  • METHODS: Human hilar cholangiocarcinoma cells KKU-100 were treated with PI3K inhibitors, and cell viability and apoptosis assays were performed.
  • The expression of a MAPK phosphatase (MKP-1) that contributes to cancer cell survival in response to multiple stress stimuli was assayed by quantitative real-time RT-PCR and western blotting.
  • Simultaneous targeting of the PI3K pathway and MKP-1 may be a useful approach to improve therapies directed against hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Dual Specificity Phosphatase 1 / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Chromones / pharmacology. Cycloheximide / pharmacology. Humans. Morpholines / pharmacology. Phosphorylation. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):253-61 [18330678.001]
  • [Cites] Crit Care Med. 2000 Apr;28(4 Suppl):N67-77 [10807318.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3335-45 [16462770.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):660-7 [19147772.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):509-14 [16922617.001]
  • [Cites] Gastroenterology. 2000 May;118(5):929-36 [10784592.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1478-90 [15448190.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;65(6):1101-7 [19707761.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4459-66 [17483361.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 30;338(4):1732-8 [16289033.001]
  • [Cites] J Biol Chem. 2009 Oct 30;284(44):30372-82 [19748889.001]
  • [Cites] Cancer Lett. 2009 Dec 28;286(2):206-16 [19553005.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27864-71 [12023956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3014-9 [9501207.001]
  • [Cites] Surg Clin North Am. 2008 Dec;88(6):1409-28, x-xi [18992602.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Apr;97(4):465-70 [15088030.001]
  • [Cites] Hepatology. 2004 Mar;39(3):732-8 [14999691.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21534-41 [12676937.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1255-65 [19175673.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3639-49 [15173070.001]
  • [Cites] Cancer Cell Int. 2009 Jan 08;9:3 [19128511.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10 ):1561-8 [17461449.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):590-9 [18057991.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3191-8 [19755862.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):631-5 [18086631.001]
  • [Cites] Pharmacol Rev. 2008 Sep;60(3):261-310 [18922965.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3392-7 [15948244.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):579-85 [17717636.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):517-23 [15099972.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3530-9 [19417026.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(1):33-47 [16807678.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(5):1084-92 [11682457.001]
  • (PMID = 20145951.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromones; 0 / Morpholines; 31M2U1DVID / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 98600C0908 / Cycloheximide; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.48 / DUSP1 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


16. Fukunaga K, Yamaguchi K, Kawada I, Inoue T, Takeshita K, Oyamada Y, Kameyama K, Yamazaki K: [A case of squamous cell lung cancer in a nonsmoking female, successfully treated with docetaxel and cisplatin]. Gan To Kagaku Ryoho; 2000 Jan;27(1):139-42
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell lung cancer in a nonsmoking female, successfully treated with docetaxel and cisplatin].
  • Chest X-ray and CT examinations revealed a large tumor, located adjacent to a cystic lesion in the left lower lung field, in association with a clearly recognizable swelling of the ipsilateral hilar as well as the mediastinal lymph nodes.
  • Sputum cytology after bronchofiberscopy led to the diagnosis that the patient suffered from squamous cell lung cancer of Stage IIIA with bulky N2 (T2N2M0).
  • Chemotherapy was selected as the most reasonable treatment for this patient.
  • The new chemotherapeutic agent docetaxel (60 mg/m2) in combination with cisplatin (CDDP: 80 mg/m2) was tried, resulting in a remarkable reduction in tumor size by 60% after the initial course of chemotherapy was completed, which fulfilled the definition of a partial response (PR).
  • Furthermore, after 4 courses of the chemotherapy, the hilar and mediastinal lymphadenopathy had conspicuously abated and only scar tissue was visible at the site where the lung cancer was thought to have originally developed.
  • We herein report a case in which squamous cell lung cancer sprouted in a nonsmoking female, who was successfully treated by the combined chemotherapy of docetaxel and CDDP.
  • The present case may suggest the efficacy of newly developed docetaxel in treating non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660748.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Ishida M, Nakama T, Shimazaki T, Tanaka T, Tsuchihashi Y, Morimoto K: [An autopsied case of pulmonary clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2010 May;48(5):364-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsied case of pulmonary clear cell adenocarcinoma].
  • We report a case of a 72-year-old woman who died of primary lung clear cell adenocarcinoma.
  • Chest computed tomography (CT) showed a tumor shadow and collapsed portion in the left hilar area.
  • Chemotherapy with carboplatin and paclitaxel was initiated, but no improvement was obtained.
  • According to previous reports in the literature, cases of primary lung clear cell adenocarcinoma are very rare.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560438.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Murphy AM, McKiernan JM: Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol; 2009 Aug;27(4):501-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor.
  • METHODS: A PubMED and Medline search was performed to identify reoperative retroperitoneal surgery series for patients with nonseminomatous germ cell tumor.
  • RESULTS: A reliance on cisplatin-based chemotherapy to treat residual disease after RPLND is inadequate for most patients.
  • The left para-aortic and left renal hilar regions are the most common sites of retroperitoneal failure.
  • Clinical outcomes after reoperative RPLND are influenced by serum tumor markers, histologic findings and completeness of surgical resection.
  • [MeSH-major] Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Neoplasm Metastasis / prevention & control. Reoperation / methods. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):851-8 [16614875.001]
  • [Cites] Eur Urol. 2002 Sep;42(3):221-8; discussion 228 [12234506.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):64-71 [15582251.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4365-9 [17906201.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1824-33 [6090001.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):976-80 [7853586.001]
  • [Cites] J Urol. 2002 Jan;167(1):94-6 [11743283.001]
  • [Cites] Semin Urol. 1988 Aug;6(3):233-7 [3244967.001]
  • [Cites] J Urol. 1995 Jan;153(1):85-9 [7966799.001]
  • [Cites] Semin Surg Oncol. 1999 Dec;17(4):263-7 [10588855.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2108-13 [2421864.001]
  • [Cites] Cancer. 1974 Feb;33(2):340-8 [4855872.001]
  • [Cites] Urology. 2003 Oct;62(4):732-6 [14550453.001]
  • [Cites] Urology. 1999 Sep;54(3):548-52 [10475370.001]
  • [Cites] Br J Urol. 1998 Feb;81(2):301-8 [9488076.001]
  • [Cites] J Urol. 1987 Jul;138(1):77-82 [3599225.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):235-43; abstract x [17484928.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):100-1 [12620901.001]
  • [Cites] J Urol. 2003 May;169(5):1710-4 [12686815.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1982 Aug;128(2):315-20 [7109099.001]
  • [Cites] Urology. 1993 Jul;42(1):31-4 [8392234.001]
  • [Cites] J Urol. 2007 Mar;177(3):937-42; discussion 942-3 [17296380.001]
  • [Cites] J Urol. 1976 May;115(5):569-71 [178934.001]
  • [Cites] Semin Urol Oncol. 2002 Nov;20(4):262-71 [12489059.001]
  • [Cites] J Urol. 2003 Apr;169(4):1353-6 [12629359.001]
  • [Cites] BJU Int. 2007 Oct;100(4):809-12 [17711512.001]
  • (PMID = 19636565.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


19. Chen D, Zhang X, Yin W, Sun Y, Miao Y, Feng F, Wang J, Wang M, Zhang H, Feng Q, Xu B, Shi Y: [Results of combined therapy for 1260 patients with small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2002 Nov;24(6):602-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of combined therapy for 1260 patients with small cell lung cancer].
  • OBJECTIVE: To evaluate the efficacy of combined modality treatment and determine the prognostic factors for small cell lung cancer (SCLC).
  • 553 patients were alloted into chemotherapy + radiotherapy (C + R) group, 355 into C + R + C group, 97 into R + C group, 126 into C group, 64 into R group and 65 into surgery (S + C + R) group.
  • Patients with limited lesions received 2 - 4 cycles of chemotherapy including COMC, COMP, COMVP and CE-CAP.
  • Radiotherapy was given to a dose of 40 - 70 Gy/4 - 7 w.
  • Radiation portals for patients with limited lesions encompassed the primary tumor, hilar lymphatic drainage areas, partial mediastinum and bilateral supraclavicular regions.
  • Patients with extensive lesions mainly received chemotherapy with or without palliative irradiation.
  • The 1-, 3- and 5-year survival rates were 50.2%, 14.7% and 11.7%, with median survival time of 12 months.
  • The era, sex, age, tumor stage and treatment modality were all significant prognostic factors by both uni-variate and multi-variate analyses (P < 0.05).
  • The result of S + C + R rated the best among these modalities and the result of C + R + C was superior to C + R, though the difference of which was not significant.
  • CONCLUSION: Surgical resection should be considered as one part of comprehensive therapy for small cell lung cancer patients with limited lesions whenever possible.
  • On top of routine chemotherapy early administration of radiotherapy is advisable.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12667336.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • The patient was administered chemotherapy with 5-fluorouracil and cisplatin (5-FU/CDDP) to the metastatic lymph node.
  • However, the treatment response was graded as progressive disease, and the treatment was changed from CDDP to mitomycin C (MMC).
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage


21. Chang ST, Hsieh YC, Lu YH, Tzeng CC, Lin CN, Chuang SS: Floral leukemic cells transformed from marginal zone lymphoma. Pathol Res Pract; 2008;204(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are three clinicopathological entities of marginal zone lymphoma (MZL), including extranodal or mucosa-associated lymphoid tissue (MALT) lymphoma and MZL of nodal (NMZL) or splenic (SMZL) type.
  • We present a stage 4 MZL involving lymph node, spleen, and bone marrow with two relapses after chemotherapy.
  • The leukemic cells at the second relapse revealed irregular nuclear contours with multilobated nuclei (so-called flower cells or floral cells) mimicking the neoplastic cells in adult T-cell leukemia/lymphoma (ATLL).
  • The absence of leukemic change and splenic hilar lymphadenopathy at initial presentation, expression of IgD by tumor cells, and cytogenetic changes of +7 suggested that this tumor might be a NMZL.
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymph Nodes / pathology. Lymphocytes / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Spleen / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cell Nucleus / pathology. Cytogenetics. Diagnosis, Differential. Fatal Outcome. Gene Expression Regulation, Neoplastic. Humans. Immunoglobulin D / analysis. Male. Radiotherapy. Recurrence. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913385.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin D
  •  go-up   go-down


22. Kubota Y: [A case of large-cell lung cancer with marked leukocytosis successfully treated with chemoradiotherapy]. Gan To Kagaku Ryoho; 2004 May;31(5):751-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of large-cell lung cancer with marked leukocytosis successfully treated with chemoradiotherapy].
  • A 45-year-old woman was transferred to our hospital for further examination of a persistent fever, marked leukocytosis and abnormal shadow on chest CT scan.
  • At the time of admission, her leukocyte count was 48,800/microliter and her chest CT scan showed a solitary nodule in the right upper lobe with hilar and mediastinal lymphadenopathy.
  • A US-guided biopsy revealed a large-cell carcinoma.
  • She was given radiation (total 60 Gy) and 4 courses of chemotherapy with paclitaxel (150 mg/m2) in combination with carboplatin (AUC = 5).
  • The primary tumor and swollen lymph nodes disappeared and leukocyte count normalized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Leukocytosis / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Radiography, Thoracic. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15170986.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Hasturk S, Soylu M, Zeren EH, Hanta I: Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor. Lung Cancer; 2001 Apr;32(1):95-101
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor.
  • Chest radiography revealed a left hilar mass and pleural effusion in the left hemithorax.
  • A computed tomography (CT) confirmed the mass in the left hilum and multiple mass lesions consistent with metastasis in the liver and in the body of 12th thoracic vertebra.
  • Bronchoscopic biopsies revealed large cell carcinoma with basaloid features.
  • He died after 4 months with rapid progression of the disease in spite of combined chemotherapy.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Lung Neoplasms / pathology. Uveal Neoplasms / pathology. Uveal Neoplasms / secondary
  • [MeSH-minor] Carboplatin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Paclitaxel / therapeutic use. Pleural Effusion, Malignant / pathology. Smoking / adverse effects. Tomography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282434.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Seok JY, Lee KG: Cytologic features of metastatic lymphoepithelial carcinoma in pleural fluid: a case report. Acta Cytol; 2009 Mar-Apr;53(2):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphoepithelial carcinoma of the salivary gland is a rare undifferentiated or poorly differentiated squamous cell carcinoma associated with abundant inmphocytes.
  • CASE: A 29-year-old man presented with a painless mass in his right parotid gland.
  • After the surgical specimen was evaluated, the mass was diagnosed as a lymphoepithelial carcinoma, which extended to the periglandular soft tissue with lymph node metastasis.
  • Despite radiation and chemotherapy, multiple mediastinal lymph node metastases, including in the right hilar lymph nodes, occurred.
  • Pulmonary atelectasis of the right upper lobe and a right pleural effusion developed.
  • Aspiration cytology of metastatic lymph nodes and pleural effusion cytology both demonstrated strongly cohesive clusters of tumor cells.
  • CONCLUSION: Pleural effusion cytopathology ofmetastatic lymphoepithelial carcinoma is similar to that of primary tumor fine needle aspiration.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Parotid Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365979.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Yonemori K, Kunitoh H, Sekine I: Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker. Nat Clin Pract Oncol; 2006 Jul;3(7):399-403; quiz following 403
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker.
  • BACKGROUND: An asymptomatic 18-year-old female presented in December 2002 with a left pulmonary mass, and an enlarged mediastinum and left hilum, detected on a routine chest X-ray.
  • A CT scan of the chest disclosed a round tumor in the left lower lobe and marked enlargement of the ipsilateral hilar and mediastinal lymph nodes.
  • INVESTIGATIONS: CT scan of the chest, routine hematological study, sputum smear and culture for acid-fast bacilli, transbronchial lung biopsy, serum tumor markers, CT scan of the abdomen, MRI scan of the head, bone scintigraphy, lung function tests, blood gas analysis, pathological examination including hematoxylin-eosin staining and immunohistochemistry using chromogranin A, CD56 (neural cell adhesion molecule), and cytokeratin antibodies.
  • DIAGNOSIS: Limited-stage small-cell lung cancer (T1N2M0, clinical stage IIIA).
  • MANAGEMENT: Etoposide plus cisplatin chemotherapy with concurrent accelerated hyperfractionated thoracic radiotherapy, left pneumonectomy and lymph-node dissection.
  • [MeSH-major] Carcinoma, Small Cell. Lung Neoplasms. Lymphatic Diseases
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Smoking


26. Minami S, Komuta K, Asai M: [A case of amylase-producing lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2003 Oct;41(10):717-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest CT revealed a nodular lesion in the right S6 and swollen right hilar lymph nodes.
  • A subsequent biopsy of a subcutaneous mass in the left lateral pectoral region demonstrated metastatic cancer.
  • Amylase isozyme patterns identified the salivary types.
  • Chemotherapy failed to prevent tumor progression and the patient eventually died of respiratory failure.
  • Immunohistological examination of the subcutaneous lesion showed positive staining for salivary-type amylase, whereas that of the lung primary lesion disclosed small cell carcinoma and negative staining for amylase.
  • Amylase-producing small cell carcinoma is very rare.
  • [MeSH-major] Amylases / biosynthesis. Carcinoma, Small Cell / enzymology. Lung Neoplasms / enzymology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Fatal Outcome. Humans. Isoenzymes / analysis. Isoenzymes / biosynthesis. Male. Neoplasms, Connective Tissue / secondary. Subcutaneous Tissue

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584392.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 3.2.1.- / Amylases
  •  go-up   go-down


27. Shimamura M, Yamaguchi S, Kuroiwa Y: [A Lambert-Faton myasthenic syndrome and subacute cerebellar degeneration with a favorable clinical course after resection of small-cell lung cancer]. Rinsho Shinkeigaku; 2000 Oct;40(10):1028-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Lambert-Faton myasthenic syndrome and subacute cerebellar degeneration with a favorable clinical course after resection of small-cell lung cancer].
  • A case of Lambert-Eaton myasthenic syndrome (LEMS) and subacute cerebellar degeneration (SCD) was associated with small-cell lung cancer (SCLC).
  • A chest x-ray showed a mass lesion in the left hilar region, and small cell lung cancer was diagnosed on the basis of biopsy specimens.
  • The patient was treated by lobectomy and chemotherapy, which resulted in improvement in the LEMS and SCD.
  • But we propose that anti-neoplastic treatment including resection of the tumor is the first choice for the treatment of paraneoplastic syndrome associated with SCLC.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lambert-Eaton Myasthenic Syndrome / therapy. Lung Neoplasms / surgery. Paraneoplastic Cerebellar Degeneration / therapy


28. Quaglia MP, Brennan MF: The clinical approach to desmoplastic small round cell tumor. Surg Oncol; 2000 Aug;9(2):77-81
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical approach to desmoplastic small round cell tumor.
  • BACKGROUND AND OBJECTIVES: Desmoplastic small round cell tumor (DSRCT) is an increasingly recognized entity with a historically poor prognosis.
  • METHODS: We retrospectively reviewed our experience with 40 histologically proven cases of desmoplastic small round cell tumor diagnosed between 7/1/72 and 10/1/99.
  • Thirty-five of these patients are the subjects of a previous report.
  • There is a significant correlation between use of intense alkylator therapy (P6 protocol), and gross total resection with improved overall survival.
  • Extensive hepatic parenchymal or hilar involvement or extensive infiltration of the diaphragm in the region of the septum transversum and hepatic veins usually makes gross total resection impossible with a corresponding worsened prognosis.
  • CONCLUSION: We recommend induction chemotherapy (P6) followed by aggressive surgical debulking and external beam radiotherapy for the treatment of DSRCT.
  • Further progress will require new forms of treatment.
  • [MeSH-major] Abdominal Neoplasms / therapy. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Female. Humans. Laparotomy. Male. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094327.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


29. Wakahashi K, Shimoyama M, Katayama Y, Minagawa K, Yoshida K, Sasaki R, Nakayama S, Yokozaki H, Yanagita E, Itoh T, Hayashi Y, Matsui T: Histiocytic sarcoma with two immunohistopathologically distinct populations. Int J Hematol; 2010 Nov;92(4):642-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report is a case of histiocytic sarcoma (HS), in which tumor cells consist of two immunohistopathologically distinct populations (A) oval CD68+lysozyme+CD163- cells and (B) abundant cytoplasm or spindle-shaped CD68+lysozyme-CD163+ cells.
  • Cervical lymph node was infiltrated mainly by population (A), where chemotherapy was quite effective.
  • On the other hand, vast majority of infiltrated tumor cells in the hilar lymph node belonged to population (B), in which the cells were resistant to chemo-radiotherapy.
  • It is also notable that CD163-negative stage of HS may exist and still be reactive for the treatment.
  • [MeSH-minor] Aged. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Cell Shape. Fatal Outcome. Humans. Lymph Nodes / chemistry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Muramidase / analysis. Receptors, Cell Surface / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2010 Mar;16(1):127-32 [19655275.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):699-703 [2163361.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1883-90 [9712057.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):932-3 [17617785.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Int J Hematol. 2010 Jul;92(1):168-73 [20535595.001]
  • [Cites] Immunobiology. 2006;211(6-8):419-25 [16920481.001]
  • [Cites] Blood. 2009 Jan 22;113(4):887-92 [18849484.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):198-201 [11196644.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):338-44 [18987551.001]
  • [Cites] Am J Surg Pathol. 2010 Apr;34(4):589-94 [20216376.001]
  • [Cites] Mod Pathol. 2005 May;18(5):693-704 [15696128.001]
  • [Cites] Diagn Pathol. 2007 Feb 26;2:7 [17324277.001]
  • [Cites] Int J Hematol. 2009 May;89(4):529-32 [19343479.001]
  • [Cites] Leuk Res. 2010 Feb;34(2):e71-3 [19744706.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5433-9 [18272816.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):301-5 [17284118.001]
  • [Cites] Immunology. 1997 Dec;92(4):478-86 [9497489.001]
  • [Cites] Blood. 2009 Oct 1;114(14):3113-6 [19643987.001]
  • [Cites] Acta Oncol. 2008;47(3):466-9 [18348004.001]
  • [Cites] Int J Hematol. 2008 Jan;87(1):83-7 [18224419.001]
  • [Cites] Int J Hematol. 2004 Nov;80(4):365-9 [15615263.001]
  • [Cites] Intern Med. 2008;47(3):165-9 [18239326.001]
  • [Cites] Pathol Res Pract. 2007;203(9):683-9 [17673373.001]
  • [Cites] Diagn Cytopathol. 2010 May;38(5):351-6 [19845032.001]
  • [Cites] Int J Hematol. 2008 May;87(4):405-9 [18327679.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):841-3 [11688984.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):794-801 [15491976.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):93-6 [12208511.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2320-5 [8370408.001]
  • (PMID = 20924729.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / CD68 antigen, human; 0 / Receptors, Cell Surface; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


30. Yamaguchi H, Soda H, Kitazaki T, Nakano H, Fujino S, Nakamura Y, Kohno S: Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer. Respirology; 2007 Jan;12(1):137-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer.
  • A 65-year-old male smoker with severe COPD was diagnosed with limited-stage small-cell lung cancer.
  • During follow up, serum ProGRP levels increased, and a whole-body FDG-PET scan detected recurrence at the hilar lymph node that had been negative on CT.
  • Complete remission was again achieved with second-line chemotherapy (cisplatin/etoposide) and local irradiation to the hilar lymph node.
  • Monitoring serum ProGRP levels, followed by whole-body FDG-PET when indicated, may improve the clinical management of patients with small-cell lung cancer after initial complete remission.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Small Cell. Lung Neoplasms. Neoplasm Recurrence, Local. Peptide Fragments / blood. Peptides / blood. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207039.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


31. Chandra V, Allen MS, Nichols FC 3rd, Deschamps C, Cassivi SD, Pairolero PC: The role of pulmonary resection in small cell lung cancer. Mayo Clin Proc; 2006 May;81(5):619-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of pulmonary resection in small cell lung cancer.
  • OBJECTIVE: To analyze the outcome of surgical resection for patients with small cell lung cancer (SCLC).
  • Operations performed included thoracotomy with biopsy of hilar mass in 10 patients, wedge excision in 30 (6 with talc pleurodesis), segmentectomy in 4, lobectomy in 28, bilobectomy in 3, and pneumonectomy in 2.
  • Postoperative therapy Included chemotherapy alone in 20 patients, radiation therapy in 3, and combined chemotherapy and radiation therapy in 40.
  • Median tumor diameter was 4 cm (range, 1.0-10.0 cm).
  • Postsurgical tumor stage was IA in 7 patients, IB in 11, IIA in 8, IIB in 7, IIIA in 30, IIIB in 10, and IV in 4.
  • Overall median survival was 24 months; median survival for patients who underwent curative surgery was 25 months compared with 16 months for those who had a palliative procedure (P=.34).
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Analysis. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706259.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Benchekroun A, Zannoud M, el Alj HA, Nouini Y, Marzouk M, Faik M: [Clear cell sarcoma of the kidney: 3 case reports]. Prog Urol; 2002 Jun;12(3):469-73
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell sarcoma of the kidney: 3 case reports].
  • [Transliterated title] Sarcome à cellules claires du rein (à propos de trois observations).
  • Clear cell carcoma of the kidney is a distinct, highly malignant pediatric neoplasm.
  • MATERIAL AND METHODS: We report 3 cases of clear cell sarcoma of the kidney in one men and two women between 23 and 65 years old (mean age is 40 years).
  • A radical nephrectomy with hilar lympgh node dissection was accomplished.
  • A combination chemotherapy regiment (cisplatin and doxorubicin) was performed on 6 cycles in 1 case.
  • The other 2 case was not underwent chemotherapy or radiation.
  • RESULTS: In the patient underwent the combination chemotherapy there was not evidence of tumor in the abdomen and thorax on CT Scan 4 years later.
  • In one of the two patient not underwent chemotherapy or radiation, the CT scan revealed a left psoas reccurrence three month later; therapy consisted for surgery without chemotherapy or radiation.
  • The other patient not underwent chemotherapy or radiation was dead seven month after nephrectomy.
  • CONCLUSION: Optimal treatment is unknown, and surgery; radiotherapy and chemotherapy are used alone but mostly in combination.
  • [MeSH-major] Kidney Neoplasms. Sarcoma, Clear Cell
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12189758.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Deslauriers J, Grégoire J: Surgical therapy of early non-small cell lung cancer. Chest; 2000 Apr;117(4 Suppl 1):104S-109S
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy of early non-small cell lung cancer.
  • Approximately 45% of all lung carcinomas are limited to the chest, where surgical resection is not only an important therapeutic modality, but in many cases, the most effective method of controlling the disease.
  • Patients with T1N0 and T2N0 tumors have early lung cancer, and most are curable by resection, with 5-year survival rates in the range of 75 to 80% for patients with T1N0 status.
  • Patients with smaller tumors do better than patients with larger ones, while visceral pleural invasion does not seem to influence survival.
  • Histologic type is also a significant prognostic variable, with squamous tumors having a better prognosis than tumors of nonsquamous histology.
  • The "gold standard" of surgery remains lobectomy, regardless of tumor size at presentation.
  • Stage T1N1 and T2N1 carcinomas represent a group of patients where the disease involves hilar and bronchopulmonary nodes.
  • Tumor size and histology are significant prognostic variables, and 5-year survival after complete resection is in the range of 40 to 50%.
  • Postoperative radiation therapy may improve local control, while chemotherapy results in a slightly reduced risk of death.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Pneumonectomy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10777463.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 54
  •  go-up   go-down


34. McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, Sheinfeld J: Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology; 2003 Oct;62(4):732-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.
  • OBJECTIVES: To describe the clinical characteristics and outcome of patients with metastatic nonseminomatous germ cell tumor requiring reoperative retroperitoneal surgery at the Memorial Sloan-Kettering Cancer Center, because such patients are poorly characterized.
  • METHODS: The Memorial Sloan-Kettering Cancer Center germ cell tumor surgical database was reviewed from January 1989 through April 2001, and the clinical characteristics of patients undergoing reoperative retroperitoneal surgery for nonseminomatous germ cell tumor were identified.
  • Left testicular primary tumors were more common than right (33 versus 23), and the most common sites of disease prompting reoperation were the para-aortic and left hilar regions.
  • Teratoma was the most common histologic finding at the time of reoperation.
  • Of 56 patients, 37 (66%) required chemotherapy between the initial operation and reoperation.
  • Sixty-nine percent of patients required adjunctive procedures at the time of reoperation, the most common of which was thoracotomy.
  • CONCLUSIONS: Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor can be performed with acceptable morbidity in select referral centers.
  • Teratoma is highly prevalent in the retroperitoneum at the time of reoperation.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Lymph Node Excision. Reoperation / statistics & numerical data. Salvage Therapy / statistics & numerical data. Testicular Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / utilization. Combined Modality Therapy. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. New York City / epidemiology. Organoplatinum Compounds / administration & dosage. Postoperative Complications / epidemiology. Prospective Studies. Retroperitoneal Space. Survival Analysis. Teratoma / mortality. Teratoma / secondary. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14550453.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


35. Rosell R, Green M, Gumerlock P: Advances in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin Oncol; 2001 Feb;28(1 Suppl 2):28-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
  • Increasing evidence that non-small cell lung cancer is a systemic disease from the outset confirms the rationale for adjuvant chemotherapy.
  • The position is clearer in the case of neoadjuvant therapy because long-term follow up of two trials now shows that patients randomized to chemotherapy before surgery were significantly more likely to survive to 5 years than patients treated with surgery alone.
  • Early data suggest that neoadjuvant chemotherapy based on docetaxel (Taxotere; Aventis, Antony, France) (possibly used sequentially with other agents) may be as effective as older regimens and better tolerated.
  • Because p53 status influences the expression of microtubule-associated proteins and hence the sensitivity of a tumor to taxanes, it is possible that molecular markers could be used to customize chemotherapy to individual patients.
  • Generally, it is becoming clearer that molecular staging is a more sensitive means of demonstrating tumor dissemination than light microscopy.
  • The Cancer and Leukemia Group B is undertaking a prospective study using reverse transcriptase-polymerase chain reaction to detect MUC-1 RNA in bone marrow and hilar and mediastinal lymph nodes removed at resection with the aim of distinguishing between stage I patients likely to remain disease-free for long periods and those at high risk of relapse.
  • A study of small cell lung cancer is using automated fluorescence microscopy to detect keratin-positive cells in the marrow and blood of patients who have a complete response to initial therapy but are nevertheless at high overall risk of relapse.
  • The identification of genetic lesions in a high proportion of patients with non-small cell lung cancer may guide the development of new therapies aimed at increasing rates of apoptosis among tumor cells.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / metabolism. Lung Neoplasms / therapy. Neoplasm Proteins / metabolism. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cell Cycle Proteins / metabolism. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Staging. Nuclear Proteins / metabolism. Proto-Oncogene Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284622.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 34
  •  go-up   go-down


36. Vanneste BG, Haas RL, Bard MP, Rijna H, Váldes Olmos RA, Belderbos JS: Involved field radiotherapy for locally advanced non-small cell lung cancer: isolated mediastinal nodal relapse. Lung Cancer; 2010 Nov;70(2):218-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved field radiotherapy for locally advanced non-small cell lung cancer: isolated mediastinal nodal relapse.
  • The current standard of care for locally advanced inoperable non-small cell lung cancer is high dose radiotherapy with concurrent chemotherapy.
  • We report on a patient with stage IIIA NSCLC treated with concurrent chemoradiotherapy on the primary tumor and the 18-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) positive hilar and mediastinal lymph nodes.
  • Six months after treatment this patient developed a single isolated contralateral mediastinal nodal relapse outside but in the proximity of the irradiated target volume.
  • This case describes the clinical problem of a regional recurrence after involved field radiotherapy that occasionally occurs.
  • A possible explanation for those regional recurrences is an under staging of extension of the disease because the time-interval between the staging (18)FDG-PET-CT scan and the start of the irradiation was too long.
  • If the time-interval is 4 weeks or more, we strongly recommend a new (18)FDG-PET-CT because of the possibility of upstaging of the disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Recurrence, Local
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Protocols. Disease Progression. Disease-Free Survival. Humans. Male. Mediastinum / pathology. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20832897.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


37. Fox J, Ford E, Redmond K, Zhou J, Wong J, Song DY: Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):341-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer.
  • PURPOSE: Dose escalation for lung cancer is limited by normal tissue toxicity.
  • We evaluated sequential computed tomography (CT) scans to assess the possibility of adaptively reducing treatment volumes by quantifying the tumor volume reduction occurring during a course of radiotherapy (RT).
  • METHODS AND MATERIALS: A total of 22 patients underwent RT for Stage I-III non-small-cell lung cancer with conventional fractionation; 15 received concurrent chemotherapy.
  • Two repeat CT scans were performed at a nominal dose of 30 Gy and 50 Gy.
  • The gross tumor volume (GTV) was delineated on simulation and all individual phases of the repeat CT scans.
  • Parenchymal tumor was evaluated unless the nodal volume was larger or was the primary.
  • The volume reduction was not significantly different between patients receiving chemoradiotherapy vs. RT alone, a GTV >100 cm(3) vs. <100 cm(3), and hilar and/or mediastinal involvement vs. purely parenchymal or pleural lesions.
  • These observations raise the possibility of using an adaptive approach toward RT of non-small-cell lung cancer to minimize the dose to normal structures and more safely increase the dose directed at the target tissues.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Tumor Burden / radiation effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Humans. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038504.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cibeira MT, Lopez-Guillermo A, Colomer D, Ricart MJ, Alcaraz A, Martinez A, Campo E, Montserrat E: Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. Ann Hematol; 2003 Feb;82(2):131-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation.
  • A patient with both a renal and pancreatic transplantation developed a diffuse large B-cell lymphoma, Epstein-Barr virus-related, 14 months after the surgical procedure.
  • Tumor was confined to the transplanted organs: head of the pancreas and hilar lymph node of the transplanted kidney.
  • Chimerism analysis demonstrated the tumor origin from donor lymphoid cells.
  • Immunosuppression was discontinued and chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) was started.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / virology. Pancreas Transplantation / adverse effects


39. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR: Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer; 2010 Nov 1;116(21):5038-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer.
  • BACKGROUND: The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%-50%.
  • Adjuvant chemotherapy was given to 7%.
  • On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


40. Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F: Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg; 2008 May;33(5):829-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
  • INTRODUCTION: Optimal preoperative treatment of stage IIB (Pancoast)/III non-small cell lung cancer (NSCLC) remains undetermined and a subject of controversy.
  • The goal of our study is to confirm feasibility and pathological response rates after induction chemoradiation (CRT) in our community-based treatment center.
  • Induction treatment comprised 3D conformal 4500 cGy radiotherapy delivered to the primary tumor and pathologic hilar and/or mediastinal lymph nodes on CT scan with an extra-margin of 1-1.5 cm.
  • Concurrent chemotherapy regimen was cisplatinum 20mg/m2 d1-d5 and etoposide 50mg/m2 d1-d5, d1-5 d29-33.
  • Inoperable pts were referred for a 20-25 Gy boost +/-1 extra-cycle of cisplatinum+etoposide.
  • RESULTS: From 1996 to 2005, 107 pts were initially selected for treatment and received induction chemoradiation (stage IIB-Pancoast 18, IIIA 58 and IIIB 31, squamous cell carcinoma 48%, adenocarcinoma 44%, large-cell undifferentiated carcinoma 14%).
  • After preoperative evaluation, 72 pts (67%) had a thoracotomy (pneumonectomy 21, lobectomy 45, bilobectomy 5) and all but one (unresectable tumor) had a macroscopic complete resection.
  • During the 3-month postoperative time, five patients (6.9%) died, four after pneumonectomy (right 3, left 1).
  • Median follow-up time was 22.3 months (survivors: 36.8 months), 2-year and 3-year overall survival rates were 55% and 40%, respectively (median=26.7 months) for all the intention-to-treat population (n=107), 62% and 51% (median=36.5 months) for 71 resected pts, 41% and 16% for 36 non-resected pts (median=19.1 months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Lung Neoplasms / drug therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pneumonectomy. Proportional Hazards Models. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367406.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


41. Smythe WR, American College of Chest Physicians: Treatment of stage I non-small cell lung carcinoma. Chest; 2003 Jan;123(1 Suppl):181S-187S
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of stage I non-small cell lung carcinoma.
  • The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma (NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no evidence of hilar or mediastinal nodal disease (N0) or metastatic spread (M0).
  • Medically fit patients in this clinical stage category based on conventional staging techniques should be considered for aggressive local therapy, and curative treatment is possible.
  • Surgical resection is the accepted treatment for patients with this stage grouping, and full lobar or greater (lobectomy, pneumonectomy) rather than sublobar (wedge resection, segmentectomy) resection is strongly suggested.
  • The performance of a systematic sampling or full mediastinal lymph node dissection may improve pathologic staging but is unproven therapeutically.
  • There are no data supporting the routine use of chemotherapy in an adjuvant or neoadjuvant setting; however, recent phase II data suggest that neoadjuvant chemotherapy is feasible and safe, and larger phase III trials are now evaluating this modality.
  • Primary radiation therapy should be considered for inoperable patients.
  • The use of neoadjuvant or adjuvant radiation therapy in patients with stage I NSCLC is of unproven benefit.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy / methods. Evidence-Based Medicine. Humans. Neoplasm Staging. Pneumonectomy / methods. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527578.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


42. Uruga H, Morokawa N, Enomoto T, Takaya H, Miyamoto A, Kishi K, Kurosaki A, Fujii T, Yoshimura K: [A case of pulmonary tumor thrombotic microangiopathy associated with lung adenocarcinoma diagnosed by CT-guided lung biopsy]. Nihon Kokyuki Gakkai Zasshi; 2008 Nov;46(11):928-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary tumor thrombotic microangiopathy associated with lung adenocarcinoma diagnosed by CT-guided lung biopsy].
  • Chest X-ray and CT scan revealed a 17-mm nodule in the left upper lobe, consolidations in both lower lobes, and mediastinal and hilar lymphadenopathy.
  • CT-guided lung biopsy from the right lower lobe revealed tumor cell embolism, intimal fibrocellular proliferation of small arteries, fibrin thrombi and recanalization.
  • Embolic tumor cells were adenocarcinoma and immunohistologial staining for TTF-1 was positive.
  • The patient was diagnosed as having pulmonary tumor thrombotic microangiopathy (PTTM) associated with clinical stage IV primary lung adenocarcinoma.
  • Although chemotherapy with carboplatin and paclitaxel resulted in improvement of pulmonary consolidations, multiple bone metastatic lesions appeared.
  • This suggests that CT-guided lung biopsy may be useful for diagnosis of PTTM, and enable establishment of appropriate cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy / methods. Lung / blood supply. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068768.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Tanaka K, Hara I, Takenaka A, Kawabata G, Fujisawa M: Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology; 2008 Apr;71(4):728-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included 162 radical prostatectomies, 67 radical nephrectomies, 20 partial nephrectomies, 45 nephroureterectomies, 5 retroperitoneal lymph node dissections of testicular cancers after chemotherapy, 3 radical cystectomies, and 2 other procedures.
  • RESULTS: Of the 304 patients with cancer, 4 (1.3%) developed a local recurrence, including after retroperitoneal lymph node dissection in 2 patients, radical nephrectomy in 1, and radical cystectomy in 1.
  • The histologic type of both testicular cancers was mixed germ cell tumor, with one occurring in a renal hilar lymph node and the other in a paraaortic lymph node and kidney.
  • The histologic type of the renal cell carcinoma was papillary renal cell carcinoma with sarcomatoid features (Stage pT3aN1), and it occurred in a retrocaval lymph node.
  • The histologic type of the bladder cancer was transitional cell carcinoma, Grade 3, Stage pT4aN0, and it presented as peritoneal carcinomatosis 11 months postoperatively.
  • However, two recurrences were found in 5 patients who had undergone retroperitoneal lymph node dissection for testicular cancer after chemotherapy.
  • [MeSH-major] Laparoscopy / adverse effects. Neoplasm Recurrence, Local / epidemiology. Neoplasm Seeding. Urologic Neoplasms / pathology. Urologic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279936.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Yamane Y, Tumori M, Nishiki M, Yamauti M, Yoshida M, Maruyama R, Uchida N, Kitagaki H, Kato Y: [A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy]. Gan To Kagaku Ryoho; 2002 Jun;29(6):921-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy].
  • Chest X-P and CT revealed a large tumor in the left upper lobe, in association with hilar lymphadenopathy and costal invasion.
  • Serum CEA was increased, and lung biopsy revealed a large-cell carcinoma.
  • Radiation (total 48 Gy) and 3 courses of chemotherapy with docetaxel (60 mg/m2) in combination with carboplatin (AUC = 6,600 mg) resulted in a remarkable reduction in the size of the mass, to less than 50%, and normalized serum CEA.
  • However, no tumor cells were detectable in the ablative specimen pathologically.
  • These findings suggest the efficacy of chemoradiotherapy including docetaxel with carboplatin in patients with large-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Lung Neoplasms / therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Male. Middle Aged. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12090045.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


45. Yamane Y, Tumori M, Nosaka S, Yamauti M, Tamura K, Kato Y: [A case of adrenal metastasis of lung cancer treated by carboplatin and docetaxel]. Gan To Kagaku Ryoho; 2001 Jun;28(6):835-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest X-P and CT revealed a large tumor in the right upper lobe and hilar lymphadenopathy.
  • Abdominal CT revealed bilateral adrenal tumors.
  • For continuous bloody sputum, a right upper lobectomy and lymphadenectomy were performed and the pathologic diagnosis was large cell carcinoma.
  • After surgery, we chose radiation and chemotherapy.
  • The new chemotherapeutic agent docetaxel (60 mg/m2 in combination with carboplatin (CBDCA: AUC 6,800 mg/m2) was administered, resulting in the remarkable reduction in the size of adrenal metastasis by 50% after 3 courses of chemotherapy.
  • These findings may suggest the efficacy of newly developed docetaxel in cases of non-small cell lung cancer.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432354.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


46. Kinoshita T, Inoue H, Kinouchi T, Kobayashi M, Takada T, Hara T, Hatano K, Nonomura N: Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int J Urol; 2010 Mar;17(3):286-8
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
  • We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib.
  • Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes.
  • With a short period of sorafenib administration, marked shrinkage of the renal mass and lymphadenopathy was observed after the patient experienced fulminant hepatic failure and a severe hand-foot skin reaction.
  • Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively.
  • Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy.
  • Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma.
  • At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Pyridines / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Female. Humans. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Preoperative Care. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409221.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


47. Berr F, Tannapfel A, Lamesch P, Pahernik S, Wiedmann M, Halm U, Goetz AE, Mössner J, Hauss J: Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J Hepatol; 2000 Feb;32(2):352-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma.
  • BACKGROUND: Hilar bile duct carcinoma has an 80% probability of local recurrence after curative resection, which might be reduced if neoadjuvant photodynamic therapy is feasible.
  • CASE AND TREATMENT: After intravenous injection of sodium porfimer we treated an adenocarcinoma of the proximal common bile duct (T2 N0 M0, Bismuth type II) in a 72-year-old man with red laser light (applied from the lumen at a dose 250 Joules/cm2), and the adjacent right and left hepatic and common bile duct at a dose of 125 Joules/cm2.
  • After 23 days the tumor was completely resected (adenocarcinoma pT2 pNO; G2).
  • RESULTS: In the lumenal, 4-mm-thick layer the bile duct specimen exhibited complete tumor necrosis with pigmentation of photodegraded porfimer and no viable tumor cells, while in the outer layer of the wall (at 5-8-mm depth) viable cancer cell nests without degraded porfimer were seen.
  • The bile duct tissue showed little damage.
  • Eighteen months after surgery, neither tumor recurrence nor stricture formation was found at the pretreated bilioenteric anastomoses.
  • CONCLUSIONS: a) Photodynamic therapy with sodium porfimer seems to be confined to the superficial 4-mm layer of bile duct cancer.
  • b) Neoadjuvant photodynamic therapy is feasible for hilar bile duct carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Common Bile Duct. Neoadjuvant Therapy. Photochemotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cholangiopancreatography, Endoscopic Retrograde. Combined Modality Therapy. Dihematoporphyrin Ether / therapeutic use. Feasibility Studies. Humans. Injections, Intravenous. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707878.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


48. Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K, Tsuchiya N, Miyahara Y, Yamaguchi S, Yano R, Tokunaga D, Saito H, Ubukata M, Yanagisawa T, Sugita Y, Kawabata Y: Development of sarcoidosis during etanercept therapy. Intern Med; 2008;47(11):1021-5
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of sarcoidosis during etanercept therapy.
  • This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis.
  • Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept.
  • Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy.
  • There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept.
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Etanercept. Female. Humans. Receptors, Tumor Necrosis Factor. Tomography, X-Ray Computed. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2008;47(18):1635 [18797127.001]
  • (PMID = 18520114.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  • [Number-of-references] 21
  •  go-up   go-down


49. Horikoshi M, Teshima T, Yanagimachi T, Imran MB, Nukiwa T: [Assessment of noninvasive therapy in lung cancer using lung perfusion images]. Kaku Igaku; 2000 Jan;37(1):15-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of noninvasive therapy in lung cancer using lung perfusion images].
  • The purpose of this prospective study was to follow the changes in functional parameters of radionuclide lung perfusion scans and their role in prognostication of lung cancer cases after noninvasive therapy.
  • We studied 91 patients of lung cancer treated with chemotherapy and/or radiotherapy during 1993 to 1997 in our hospital.
  • Lung perfusion scans were acquired pre and post-therapy.
  • An index of lung perfusion, called Improvement Ratio (IR) was defined as a change in the perfusion of diseased lung as a result of treatment.
  • [formula: see text] where Q and Q' are pulmonary arterial blood flow pre and post therapy respectively, p is perfusion ratio of diseased lung before therapy and q is that after therapy.
  • We further studied the relationship between IR and change in tumor size.
  • The influence of tumor location, histopathological diagnosis and prognosis of lung cancer were correlated with this newly defined index.
  • The score was significantly higher for patients with hilar disease compared to those with peripheral lesions (2.80 +/- 0.83 versus 1.02 +/- 0.03, p < 0.05).
  • Similarly, patients with small cell lung cancer depicted higher values of IR than non-small cell lung cancer (3.36 +/- 1.10 versus 1.06 +/- 0.07, p < 0.05).
  • All those subjects who showed IR > 1 had longer survival time than those with IR < 1 (p < 0.05).
  • We conclude that the evaluation of physiological parameters during therapy using lung perfusion scanning, in addition to lesion size assessment will contribute to the comprehensive follow-up of lung cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714063.001).
  • [ISSN] 0022-7854
  • [Journal-full-title] Kaku igaku. The Japanese journal of nuclear medicine
  • [ISO-abbreviation] Kaku Igaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


50. Ishimatsu Y, Takatani H, Doutsu Y, Mukae H, Kohno S: [A case of Heerfordt's syndrome with an elevated serum TNF alpha]. Nihon Kokyuki Gakkai Zasshi; 2006 Sep;44(9):636-40
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 27-year old man who had developed uveitis, swelling of the right parotid gland, right facial nerve paralysis and fever, was admitted to our hospital.
  • A chest X-ray film showed bilateral hilar lymphadenopathy.
  • Histological findings of transbronchial lung biopsy specimens showed non-caseous epithelioid cell granulomas.
  • Thus, administration of high-dose PSL for a long time was required.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Prednisolone / administration & dosage. Tumor Necrosis Factor-alpha / analysis. Uveoparotid Fever / blood. Uveoparotid Fever / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037408.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Tumor Necrosis Factor-alpha; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


51. Huang GJ, Fang DK, Cheng GY, Zhang DC: [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):62-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis].
  • OBJECTIVE: To evaluate the surgical therapeutic strategy for non-small cell lung cancer (NSCLC) with (N2) mediastinal lymph node metastasis.
  • Survival was higher in patients with radical resection than with palliative resection, with squamous-cell carcinoma than with adenocarcinoma, with sleeve lobectomy and pneumonectomy than with regular lobectomy, with 1 to 3 mediastinal metastatic lymph nodes than those over 4, and with adjuvant therapy (chiefly postoperative radiotherapy) than without.
  • There was no 5-year survivor in patients with T3 or T4 tumor, nor in those with distant metastasis.
  • CONCLUSION: It is suggested that surgery is the best choice for N2 NSCLC patients with T1 or T2 tumor, with non-adenocarcinoma, and with metastatic mediastinal lymph nodes less than 4 in number.
  • Surgery is probably not a good choice in those with T3 tumor varieties.
  • At operation, radical resection of the tumor and systematic removal of all hilar and mediastinal lymph nodes are essential for disease staging and survival improvement.
  • Adjuvant therapy may improve long-term survival and is especially indicated in patients with residual tumor and/or metastatic mediastinal lymph nodes over 3 in number.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Nodes / pathology. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737625.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Kubota T, Ikezoe T, Harada R, Nakata H, Kobayashi M, Taguchi H: [Pancreatic metastasis from lung cancer: report of an autopsy case]. Nihon Kokyuki Gakkai Zasshi; 2003 Dec;41(12):917-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A chest computed tomography (CT) scan showed a lung tumor with hilar and mediastinal lymph node swelling.
  • A CT scan of the abdomen demonstrated a solitary pancreatic head tumor with a diameter of 3 cm.
  • Pathological examination of a transbronchial biopsy specimen revealed squamous cell carcinoma (SCC) of the lung.
  • Since obstructive jaundice had progressed rapidly, the patient received endoscopic nasobiliary drainage (ENBD) and stent-drainage therapy prior to chemotherapy using gemcitabine.
  • An autopsy was performed, and microscopic and immunohistochemical examination revealed that the pancreatic tumor was a metastasis from lung cancer.
  • To our knowledge, obstructive jaundice due to pancreatic metastasis from lung SCC, especially that preceding the advent of a clinical manifestation of primary lung cancer, has rarely been reported.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Jaundice, Obstructive / pathology. Lung Neoplasms / pathology. Pancreatic Neoplasms / secondary






Advertisement